98%
921
2 minutes
20
In this study, we generated a single-chain variable fragment (scFv) specific to a potent antileukemic substance, harringtonine (HT) (HT-scFv) that can be used in enzyme-linked immunosorbent assay (ELISA) for the quantitative analysis of HT in the plant genus . The variable heavy (VH) and light chain (VL) genes were directly cloned from the cDNA of the hybridoma cell line 1D2, which secretes monoclonal antibody against HT (MAb 1D2). These genes were then assembled with a flexible peptide linker, specifically (GlySer), through splicing by overlap extension PCR. The resulting HT-scFv gene was expressed in . The denatured HT-scFv, produced as inclusion bodies, was solubilized and refolded using a dilution method to restore its functionality as an antibody. Characterization of the HT-scFv demonstrated its high specificity for HT. Additionally, its remarkable properties facilitated the development of an ELISA for HT detection, achieving a limit of detection (LOD) of 12.2 ng/mL. Furthermore, validation analyses showed that the ELISA using HT-scFv exhibited good accuracy and reliability for the quantitative assessment of HT in "Fastigiata." This study highlights the potential of HT-scFv as a valuable tool for ELISA in the quantitative analysis of HT.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1080/15321819.2025.2526208 | DOI Listing |
Int J Biol Macromol
September 2025
Department of Protein Science, Division of Protein Technology, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, AlbaNova University Center, Stockholm, Sweden. Electronic address:
This paper presents the generation and evaluation of a novel potential drug delivery platform for biologics, based on recombinant spider silk. Targeting CD40 for activation of antigen presenting cells, in order to overcome tumor induced T cell tolerance, have shown promising results in cell and animal models. However, further trials have gained limited results due to severe side reactions.
View Article and Find Full Text PDFJ Virol Methods
September 2025
Laboratorio de Inmunología, Centro de Investigación en Alimentación y Desarrollo, A.C. Hermosillo, Sonora, Mexico. Electronic address:
Bispecific antibodies (bsAbs) offer an alternative to monoclonal antibody (mAb) cocktails for addressing the loss of efficacy due to the rapid emergence of SARS-CoV-2 mutants. The structure and specificity of the parental antibodies influence the development of a highly neutralizing bsAb. To design an effective bsAb, the recognition of 44 single-chain fragment variable (scFv) antibodies against variants of SARS-CoV-2 was evaluated, along with an assessment of their ability to competitively bind to the receptor-binding domain (RBD) compared to the most potent neutralizing mAbs.
View Article and Find Full Text PDFEur J Pharm Sci
September 2025
Department of Neurology, Massachusetts General Hospital, Boston, MA, 02129, USA; Neuroscience Program, Harvard Medical School, Boston, MA, 02129, USA. Electronic address:
Glioblastoma (GBM) is a highly malignant brain tumor with limited treatment options and poor prognosis. GBM exhibits resistance to conventional therapies, including temozolomide (TMZ), radiotherapy, and immunotherapy, partly due to immunosuppressive mechanisms such as programmed death-ligand 1 (PD-L1) overexpression. To address these challenges, we developed TMZ-loaded nanostructured lipid carriers (NLCs) conjugated with anti-PD-L1 single-chain variable fragments (scFv) for dual chemo-immunotherapy.
View Article and Find Full Text PDFJ Thromb Haemost
September 2025
Blood Research Institute, Versiti, Milwaukee, WI; Department of Pharmacology & Toxicology, Medical College of Wisconsin, Milwaukee, WI; Department of Cell biology, Neurobiology, and Anatomy, Medical College of Wisconsin, Milwaukee, WI. Electronic address:
Background: Human platelets experience structural and functional deterioration during extra-corporeal storage at either room temperature or in the cold, impairing their reactivity and diminishing their hemostatic effectiveness following transfusion. PECAM-1 is an inhibitory receptor on platelets that exerts its inhibitory effects via phosphorylation of tyrosine residues that lie within its cytoplasmic immunoreceptor tyrosine-based inhibitory motifs (ITIMs). The purpose of this investigation was to attempt to restore platelet reactivity by impairing the inhibitory activity of PECAM-1.
View Article and Find Full Text PDFInt J Mol Med
November 2025
Department of Basic Medical Science, Guangxi Health Science College, Nanning, Guangxi Zhuang Autonomous Region 530023, P.R. China.
Chimeric antigen receptor (CAR) T cell therapy is a type of cellular immunotherapy showing promising clinical effectiveness and high precision. CAR‑T cells express membrane receptors with high specificity, which enable them to identify certain target antigens generated by cancerous cells. The three primary structural elements of the CAR are the extracellular domain, transmembrane domain and cytoplasmic domain.
View Article and Find Full Text PDF